<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220154</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-09115</org_study_id>
    <secondary_id>NCI-2012-00341</secondary_id>
    <nct_id>NCT01220154</nct_id>
  </id_info>
  <brief_title>Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer</brief_title>
  <official_title>Phase I Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel and Bevacizumab in Patients With Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David O'Malley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous&#xD;
      paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of&#xD;
      this regimen in previously untreated patients with advanced ovarian carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I study with the primary objective to determine the maximum tolerated dose of&#xD;
      intraperitoneal carboplatin and intravenous weekly paclitaxel given in combination with&#xD;
      intravenous bevacizumab during the second two cycles of treatment in patients with&#xD;
      chemo-naive epithelial ovarian, primary peritoneal or fallopian tube cancer. The maximum&#xD;
      tolerated dose is defined as the highest dose at which no more than 1 of 6 evaluable patients&#xD;
      experiences a dose limiting toxicity during the second two cycles of treatment. Secondary&#xD;
      objectives are to determine response rates and to estimate progression free survival and&#xD;
      overall survival of this class of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Every Cycle-28 days</time_frame>
    <description>The Maximum Tolerated Dose is defined as the highest dose at which no more than 1 of 6 evaluable patients experiences a dose limiting toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate, Progression Free Survival and Overall Survival</measure>
    <time_frame>Every 3 monthes for 2 years, Every 6 months for 3 years.</time_frame>
    <description>Response Rate in patients with measurable disease using the RECIST(Response Evaluation Criteria in Solid Tumors)criteria.&#xD;
Progression free survival is also uses the RECIST criteria or GCIG criteria. Overall survival will be followed for 5 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <condition>No Prior Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Carboplatin Paclitaxel &amp; Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.</description>
    <arm_group_label>Carboplatin Paclitaxel &amp; Bevacizumab</arm_group_label>
    <other_name>Abraxane</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intraperitoneal Day 1 cycles 1-6 AUC</description>
    <arm_group_label>Carboplatin Paclitaxel &amp; Bevacizumab</arm_group_label>
    <other_name>ParaplatinÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days</description>
    <arm_group_label>Carboplatin Paclitaxel &amp; Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histology diagnoses epithelial ovarian, primary peritoneal, or fallopian tube(Stage&#xD;
             II, III or IV)either optimal or suboptimal after initial surgery.&#xD;
&#xD;
               -  All patients must have had appropriate surgery for ovarian, peritoneal, or&#xD;
                  fallopian tube carcinoma with tissue available for histologic evaluation&#xD;
&#xD;
               -  Histologic epithelial cell types are eligible: serous adenocarcinoma,&#xD;
                  endometrioid adenocarcinoma, mucinous adenocarinoma, undifferentiated carcinoma,&#xD;
                  clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell&#xD;
                  carcinoma, malignant brenner tumor, adenocarcinoma NOS.&#xD;
&#xD;
          -  GOG(Gynecologic Oncology Group)performance status of 0,1,2&#xD;
&#xD;
          -  Entered within 12 weeks of most recent surgery performed for diagnosis.&#xD;
&#xD;
          -  Patients must have adequate bone marrow function, renal function,hepatic function,&#xD;
             neurologic function, blood coagulation parameters within normal limits&#xD;
&#xD;
          -  Sign approved consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received prior treatment other than initial surgery&#xD;
&#xD;
          -  Patients who have received prior radiotherapy to any portion of their abdominal cavity&#xD;
             or pelvis&#xD;
&#xD;
          -  Patients with acute hepatitis or active infection&#xD;
&#xD;
          -  Patients with active bleeding&#xD;
&#xD;
          -  Patients with unstable angina&#xD;
&#xD;
          -  Patients with history of invasive malignancies with the exception of nonmelanoma skin&#xD;
             cancer and localized breast cancer.&#xD;
&#xD;
          -  Patients who have received any target therapy or hormonal therapy for management of&#xD;
             their ovarian cancer.&#xD;
&#xD;
          -  Patients with synchronous primary endometrial cancer.&#xD;
&#xD;
          -  Patients with epithelial tumors of low malignant potential&#xD;
&#xD;
          -  Serious non healing wound, ulcer or bone fracture.&#xD;
&#xD;
          -  Patients with history or evidence of CNS(central nervous system disease)&#xD;
&#xD;
          -  Patients under 18 years old.&#xD;
&#xD;
          -  Patients who have received prior therapy with anti-VEGF(vascular endothelial growth&#xD;
             factor)&#xD;
&#xD;
        drug, bevacizumab&#xD;
&#xD;
          -  Patients who have a history of allergic reaction to polysorbate 80.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David O'Malley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OSU Gyn Oncology at Mill Run</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>David O'Malley</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ovarian</keyword>
  <keyword>cancer</keyword>
  <keyword>fallopian tube</keyword>
  <keyword>peritoneal</keyword>
  <keyword>intraperitoneal</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>chemo-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

